Table A3.

Treatment Characteristics for Patients With T1a,bN0 Breast Cancer, NCCN 2000-2009

Treatment Characteristic	T1aN0 Breast Cancer								T1bN0 Breast Cancer
	HR-Positive/HER2-Negative (n = 984)		HR-Positive/HER2-Positive (n = 135)		HR-Negative/HER2-Positive (n = 81)		HR-Negative/HER2-Negative (n = 99)		HR-Positive/HER2-Negative (n = 2,246)		HR-Positive/HER2-Positive (n = 199)		HR-Negative/HER2-Positive (n = 105)		HR-Negative/HER2-Negative (n = 264)
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Definitive surgery
Mastectomy	284	29	59	44	52	64	39	39	501	22	57	29	45	43	63	24
Breast-conserving surgery	699	71	76	56	29	36	60	61	1,745	78	142	71	60	57	201	76
No definitive surgery	1	< 1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Radiation therapy
No	330	34	62	46	52	64	40	40	644	29	69	35	45	43	67	25
Yes	654	66	73	54	29	36	59	60	1,602	71	130	65	60	57	197	75
Hormone therapy
No	192	20	31	23	75	93	92	93	226	10	20	10	101	96	253	96
Yes	792	80	104	77	6	7	7	7	2,020	90	179	90-	4	4	11	4
Trastuzumab
No	984	100	110	81	60	74	98	99	2,239	100	127	64	57	54	259	98
Yes	0	0	25	19	21	26	1	1	7	< 1	72	36	48	46	5	2
Chemotherapy
No	972	99	103	76	50	62	75	76	2,005	89	92	46	17	16	94	36
Yes	12	1	32	24	31	38	24	24	241	11	107	54	88	84	170	64
Type of chemotherapy
Anthracycline-containing regimen	7	58	9	28	13	42	14	58	144	60	40	37	36	41	98	58
CMF-containing regimen	0	0	0	0	0	0	0	0	11	5	2	2	2	2	8	5
Taxane-containing regimen	4	33	13	41	10	32	1	4	40	17	25	23	18	20	26	15
Anthracycline-containing regimen-taxane	0	0	4	13	4	13	7	29	39	16	23	21	23	26	34	20
Single chemotherapy agent	1	8	6	19	4	13	2	8	6	2	17	16	9	10	4	2
Other	0	0	0	0	0	0	0	0	1	< 1	0	0	0	0	0	0

Abbreviations: CMF, cyclophosphamide, methotrexate, fluorouracil; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; NCCN, National Comprehensive Cancer Network.